CMS: Receipt of Eligibility-To-List Letter from the SGX-ST

On 25 June 2025, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) received an eligibility-to-list letter (“ETL”) from the Singapore Exchange Securities Trading Limited (the “SGX-ST”) in respect of the Proposed Secondary Listing and, subject to fulfilment of the conditions set out therein, the Shares are expected to be listed and to commence trading on the SGX-ST on around 15 July 2025. The ETL is not an indication of the merits of the Proposed Secondary Listing, the Group and/or the Shares.   The Proposed Secondary Listing will not involve issuance of new Shares, and the Shares will continue to be listed and traded on the Hong Kong Stock Exchange thereafter.   The Directors believe that upon completion of the Proposed Secondary Listing on the SGX-ST, the Group will be able to attract funds focusing on Asia-Pacific investments and local capital in Southeast Asia, thereby optimizing the shareholder structure. At the same time, it will also have a more […]

China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange

The board of directors of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) announces the proposed secondary listing of the Company’s ordinary shares (“Shares”) on the Singapore Exchange Securities Trading Limited (the “SGX-ST”) by way of introduction (the “Proposed Secondary Listing”). The Proposed Secondary Listing, if proceeded, will not involve issuance of new shares, and the Shares will continue to be primarily listed and traded on the Hong Kong Stock Exchange thereafter. The Company has submitted, on a confidential basis, an application to the SGX-ST in relation to the Proposed Secondary Listing. As of the date of this announcement, the Company has not received the eligibility-to-list letter (“ETL”) from the SGX-ST in respect of the Proposed Secondary Listing. On June 24, 2025, the Company received the Notice of Overseas Issuance and Listing Filing (境外發行上市備案通知書) from the China Securities Regulatory Commission (the “CSRC”) in respect of […]

CMS Charity | Lighting Up the Stars for Exceptional Children and Rural Education with Love

As the International Children’s Day approaches, China Medical System Holdings Limited (“CMS”)  has once again partnered with the Charity Association of Shenzhen Nanshan to visit Shenzhen Nanshan Star Exceptional Children Rehabilitation Center and Shenzhen Nanshan Exceptional Children Care Center, donating dedicated funds to both institutions. The donation will be used to purchase toys and teaching aids, upgrade office facilities, and sponsor advanced training for outstanding teachers to enhance the professionalism of special education staff. CMS has continuously supported the growth and development of exceptional children, and is wholeheartedly committed to playing a role in fostering a learning environment brimming with love and warmth for the children. Simultaneously, CMS is actively responding to China’s “Hundreds, Thousands, Tens of Thousands Project,” which aims to promote rural revitalization. Through the Guangdong Education Foundation, CMS has donated a total of 18 sets of laptops and desktop computers to Caojiang No. 2 Middle School in Gaozhou for the construction of a Loving Language Laboratory, enabling students to better […]

CMS Proposes to Spin-off and Separately List the Shares of Dermavon on the Main Board of HKEX

The Company proposes to spin-off and separately list the shares of Dermavon, a subsidiary of the Company, on the Main Board of the Stock Exchange. The Proposed Spin-off, if proceeded, is expected to be implemented through a distribution in specie by the Company of all the shares in Dermavon that it holds to the Shareholders in proportion to their respective shareholding in the Company as of a record date to be determined by the Board for the purpose of ascertaining the Shareholders’ entitlements. The separate listing of the shares of Dermavon on the Stock Exchange constitutes a spin-off of Dermavon by the Company under the Practice Note 15 to the Listing Rules. The Stock Exchange has confirmed that the Company may proceed with the Proposed Spin-off. In connection with the Proposed Spin-off, on 22 April 2025, Dermavon submitted an application to the Stock Exchange for the listing of, and permission […]

China Medical System has been Included in the S&P Global Sustainability Yearbook (China Edition) for the 3rd Consecutive Year

On April 15, 2025, S&P Global officially released the Sustainability Yearbook (China Edition) 2025. China Medical System Holdings Limited (“CMS” or the “Group”) has stood out among over 1,600 Chinese companies with its outstanding performance in environmental, social, and governance (ESG) practices, marking its third consecutive year of inclusion in the Yearbook. Source: S&P Global   CMS has been implementing the concept of sustainable development into its strategy formulation and daily operation, focusing on unmet healthcare needs to provide better treatment solutions for doctors and patients, and striving to improve the accessibility and affordability of pharmaceutical products. At the same time, the Group has been continuously optimizing its internal governance, upholding the bottom line of product responsibility, respecting and empowering employees, and actively participating in public welfare, charity, and environmental protection activities, thus promoting a virtuous cycle of corporate development and responsibility fulfillment.   Through persistent dedication to sustainable development, […]

Restructuring and Breakthroughs: “New CMS” Starts a “New Journey” of Innovation丨CMS(867.HK)2024 Annual Performance Report in One Picture

IND Approval: CMS’s Self-developed Innovative Drug Cardiac Myosin Inhibitor CMS-D003 is Approved for Drug Clinical Trials

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that innovative drug CMS-D003 capsules (“CMS-D003”) self-developed by the Group has been granted approval for drug clinical trials by National Medical Products Administration of the People’s Republic of China (“NMPA”) on 11 March 2025. The approval was obtained on 12 March 2025. The NMPA grants the Group consent to conduct a clinical trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D003 in both healthy adults and adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in China.   CMS-D003 CMS-D003 is a small molecule cardiac myosin inhibitor, which is a targeted therapy for hypertrophic cardiomyopathy. By targeting inhibition of cardiac myosin adenosine triphosphate (ATP) enzymes, it inhibits myosin-actin interactions, reduces myofilament sliding, inhibits myocardial over-contraction, and improves diastolic dysfunction of the heart, thereby alleviating the patient’s clinical symptoms[1]. CMS-D003 demonstrates a short half-life, minimal risk for drug […]

China Medical System is Included in the S&P Global Sustainability Yearbook 2025

In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited (“CMS” or the “Group”) has been included in the S&P Global Sustainability Yearbook 2025 (the “Yearbook 2025”). This marks the Group’s first inclusion in the global edition of S&P Global Sustainability Yearbook (the “Yearbook”), following the S&P Global Sustainability Yearbook (China Edition) inclusion for consecutive two years.   Source: S&P Global   Since its launch in 2008, the Yearbook’s professionalism and authority have been highly recognized by global ESG investors and other stakeholders. The Yearbook aims to identify outstanding companies in sustainable development from each industry. 7,690 companies across 62 industries were assessed, while only 780 stood out and were included in the Yearbook 2025. The inclusion in the Yearbook 2025 represents a high recognition of sustainable development practices of CMS.   CMS has been actively responding […]

China Medical System Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Rα Monoclonal Antibody MG-K10

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement with Hunan Mabgeek Biotechnology Co., Ltd. (“Mabgeek Biotechnology”) and its subsidiary for Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection MG-K10 (“MG-K10” or the “Product”). The Group has obtained the co-development right as specifically agreed upon in the Agreement and exclusive commercialization right to the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore (the “Territory”); Mabgeek Biotechnology will support the commercialization activities and is responsible for the sale and supply of the Product. The collaboration term is perpetual.   IL-4Rα is considered a key target for the treatment of type 2 inflammatory diseases, such as atopic dermatitis (AD), asthma, prurigo nodularis, etc. Anti-IL-4Rα monoclonal […]

CMS Donated About RMB2.5 Million Worth of Special Fund and Supplies to Aid the Earthquake-stricken Area in Shigatse, Tibet

On 7 January 2025, a magnitude 6.8 earthquake, which struck at a depth of 10 km, hit Tingri County, Shigatse City in Tibet, causing heavy casualties and house damages. Caring about the disaster, China Medical System Holdings Limited (“CMS”) has made proactive disaster relief efforts through its wholly-owned subsidiary, Tibet Kangzhe Pharmaceutical Development Co., Ltd. On January 9th, it donated relief supplies worth nearly RMB 0.5 million to the earthquake-stricken area through Tibet Development Philanthropic Foundation, including disinfectant, military coats, cotton quilts, and cotton jackets, etc. Moreover, on January 13th, it donated a special fund of RMB2 million to Tibet Charity Federation for post-disaster resettlement and reconstruction, to further help the disaster area to overcome the difficulties sooner.   Join hands to fight the disaster, and pray for peace and safety. CMS wishes the earthquake-stricken area in Shigatse, Tibet rebuild their homes as earlier as possible.  

China Medical System Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement  (the “Agreement”)  with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or  the “Product”)  for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan and the Middle East), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years, which may be automatically renewed every five years upon the expiration unless terminated by notice from either party.   As the […]

Cultivation and Harvest: A Review of Year 2024 of China Medial System